Myrick C. Shinall, Kemberlee Bonnet, David Schlundt, Manisha Verma – 6 November 2021 – Patients undergoing evaluation for liver transplantation face heavy burdens of symptoms, health care use, and mortality. In other similarly ill populations, specialist palliative care has been shown to benefit patients, but specialist palliative care is infrequently used for liver transplantation patients. This project aims to describe the potential benefits of and barriers to specialist palliative care integration in the liver transplantation process.

Nan Wu, Guido Carpino, Ludovica Ceci, Leonardo Baiocchi, Heather Francis, Lindsey Kennedy, Tianhao Zhou, Lixian Chen, Keisaku Sato, Konstantina Kyritsi, Vik Meadows, Burcin Ekser, Antonio Franchitto, Romina Mancinelli, Paolo Onori, Eugenio Gaudio, Shannon Glaser, Gianfranco Alpini – 6 November 2021

James M. Paik, Khaled Kabbara, Katherine E. Eberly, Youssef Younossi, Linda Henry, Zobair M. Younossi – 5 November 2021

Yetirajam Rajesh, Saranya Chidambaranathan Reghupaty, Rachel G. Mendoza, Debashri Manna, Indranil Banerjee, Mark A. Subler, Korri Weldon, Zhao Lai, Shah Giashuddin, Paul B. Fisher, Arun J. Sanyal, Rebecca K. Martin, Mikhail G. Dozmorov, Jolene J. Windle, Devanand Sarkar – 4 November 2021 – Obesity is an enormous global health problem, and obesity‐induced nonalcoholic steatohepatitis (NASH) is contributing to a rising incidence and mortality for hepatocellular carcinoma (HCC).

Quan Chen, Austin Z. Chen, Guorong Jia, Jindian Li, Chuansheng Zheng, Kai Chen – 4 November 2021 – Liver cancer is one of the leading causes of cancer deaths worldwide. Among all primary liver cancers, hepatocellular carcinoma (HCC) is the most common type, representing 75%‐85% of all primary liver cancer cases. Median survival following diagnosis of HCC is approximately 6 to 20 months due to late diagnosis in its course and few effective treatment options. Interventional therapy with minimal invasiveness is recognized as a promising treatment for HCC.

Thomas H. Tranah, Victoria T. Kronsten, Debbie L. Shawcross – 4 November 2021 – Cirrhosis‐associated immune dysfunction (CAID) describes a panacea of innate and adaptive deficits that result from the sequelae of cirrhotic portal hypertension that is similar in its manifestations regardless of etiology of chronic liver injury. CAID is associated with synchronous observations of dysregulated priming of innate immune effector cells that demonstrate a proinflammatory phenotype but are functionally impaired and unable to adequately prevent invading pathogens.

Ming‐Jie Ding, Hao‐Ran Fang, Jia‐Kai Zhang, Ji‐Hua Shi, Xiao Yu, Pei‐Hao Wen, Zhi‐Hui Wang, Sheng‐Li Cao, Yi Zhang, Xiao‐Yi Shi, Hua‐Peng Zhang, Yu‐Ting He, Bing Yan, Hong‐Wei Tang, Dan‐Feng Guo, Jie Gao, Zhen Liu, Li Zhang, Shui‐Jun Zhang, Xiao‐Jing Zhang, Wen‐Zhi Guo – 3 November 2021

Romain Desert, Xiaodong Ge, Zhuolun Song, Hui Han, Daniel Lantvit, Wei Chen, Sukanta Das, Dipti Athavale, Ioana Abraham‐Enachescu, Chuck Blajszczak, Yu Chen, Orlando Musso, Grace Guzman, Yujin Hoshida, Natalia Nieto – 2 November 2021 – Osteopontin (OPN) expression correlates with tumor progression in many cancers, including hepatocellular carcinoma (HCC); however, its role in the onset of HCC remains unclear. We hypothesized that increased hepatocyte‐derived OPN is a driver of hepatocarcinogenesis.

Yongliang Yang, David Filipovic, Sudin Bhattacharya – 1 November 2021 – The cytochrome P450 (Cyp) proteins Cyp1A1 and Cyp1A2 are strongly induced in the mouse liver by the potent environmental toxicant 2, 3, 7, 8‐tetrachlorodibenzo‐p‐dioxin (TCDD), acting through the aryl hydrocarbon receptor (AHR). The induction of Cyp1A1 is localized within the centrilobular regions of the mouse liver at low doses of TCDD, progressing to pan‐lobular induction at higher doses.

Jasmine Yee, Joanne M. Carson, Behzad Hajarizadeh, Joshua Hanson, James O’Beirne, David Iser, Phillip Read, Anne Balcomb, Joseph S. Doyle, Jane Davies, Marianne Martinello, Philiipa Marks, Gregory J. Dore, Gail V. Matthews, the REACH‐C Study Group – 1 November 2021 – Australia was one of the first countries with unrestricted access to government subsidized direct‐acting antiviral (DAA) therapy for adults with chronic hepatitis C virus.